Azitra (AZTR) Research & Development (2022 - 2026)
Azitra (AZTR) posted Research & Development of $1.6 million for Q1 2026, up 55.44% on a QoQ basis from $1.0 million in Q4 2025, and up 24.84% year-over-year from $1.3 million in Q1 2025.
Azitra (AZTR) Research & Development (2022 - 2026) Analysis & Trends
Azitra's Research & Development history runs 5 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- Quarterly Research & Development rose 24.84% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 14.35% YoY) and the FY2025 annual result came in at $4.8 million, up 2.38% from the prior year.
- Research & Development was $1.6 million for Q1 2026 at Azitra, up from $1.0 million in the prior quarter.
- Across five years, Research & Development topped out at $1.7 million in Q4 2022 and bottomed at $548524.0 in Q3 2023.
- A 5-year average of $1.2 million and a median of $1.2 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 59.8% — and 2024, when it surged 85.19%.
- Azitra's Research & Development stood at $1.7 million in 2022, then retreated by 9.69% to $1.5 million in 2023, then retreated by 26.12% to $1.1 million in 2024, then slipped by 10.04% to $1.0 million in 2025, then surged by 55.44% to $1.6 million in 2026.
- Business Quant data shows AZTR's Research & Development at $1.6 million in Q1 2026, $1.0 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | 1.46 Mn |
| 3 | BeOne Medicines | 473.13 Bn | 468.34 Bn | 1.35 Bn | 541.22 Mn |
| 4 | Vertex Pharmaceuticals | 123.67 Bn | 116.43 Bn | 2.59 Bn | 961.60 Mn |
| 5 | Regeneron Pharmaceuticals | 71.57 Bn | 62.81 Bn | 3.31 Bn | 1.54 Bn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | 15.66 Mn |
| 7 | Argenx Se | 54.61 Bn | 49.42 Bn | 1.41 Bn | 1.37 Bn |
| 8 | Alnylam Pharmaceuticals | 37.99 Bn | 34.98 Bn | 959.66 Mn | 364.87 Mn |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - | 343.97 Mn |
| 10 | Azitra | 2.07 Mn | 2.07 Mn | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 1.51 Mn |
| Sep 30, 2023 | 548,524.00 |
| Jun 30, 2023 | 754,951.00 |
| Mar 31, 2023 | 829,035.00 |
| Dec 31, 2022 | 1.67 Mn |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 1.51 Mn |